HOME >> BIOLOGY >> NEWS
Accentia Biopharmaceuticals acquires exclusive license

Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) announced today that it has entered into an exclusive license with Collegium Pharmaceuticals, Inc. (Collegium) to market in the U.S., a branded intranasal steroid intended for the symptoms of seasonal and perennial allergic rhinitis . This product will be marketed by Accentia's specialty pharmaceutical division, TEAMM Pharmaceuticals. This license will expand Accentia's pipeline of innovative products for respiratory diseases and enable Accentia to enter the large intranasal steroid market. Collegium plans to file a Supplemental New Drug Application (sNDA) in 2006 for this patent-pending aqueous nasal spray formulation.

"The intranasal steroid market in the US represents approximately $2.7 billion dollars in annual sales. The primary competition for this market has been prescription non-sedating oral antihistamine products which have annual sales in excess of $4 billion dollars in the US. We anticipate that over the next several years many of the non-sedating antihistamines will migrate to the over-the-counter (OTC) marketplace. This anticipated shift in the market may benefit growth in the intranasal steroid prescription market." said Michael Heffernan, President of Collegium. "We believe that our new product will have a favorable profile within the nasal steroid market".

"This is an excellent addition to our focus on innovative products to treat respiratory diseases. Our respiratory product portfolio includes the recently announced launch of our CRSFungal ProfileTM, a unique non-invasive test for confirmation of the diagnosis of chronic sinusitis and differentiation of it from allergic rhinitis," said Martin Baum, President and COO of specialty pharmaceuticals at Accentia. "In early 2006, we expect to launch MDTurboTM , a unique, patented delivery device for metered dose inhalers used to treat asthma and chronic obstructive pulmonary disease. In addition, our pipe
'"/>

Contact: Sherran Brewer
sbrewer@accentia.net
866-481-9020
SciWords
6-Dec-2005


Page: 1 2

Related biology news :

1. FDA grants Accentia Biopharmaceuticals...
2. Accentia Biopharmaceuticals announces option agreement with Mayo
3. AutovaxID-C introduced by Accentia Biopharmaceuticals
4. Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile
5. Macrochem acquires option to license pexiganan
6. Biogen Idec acquires Brandeis spin-out
7. Wiley acquires publications from Carpe Diem Communications
8. Ossur hf. acquires the Gibaud Group in France
9. Springer acquires BioTribune Magazine and Biotribune.com
10. Stevens Davidson Laboratory acquires new research vessel
11. Ossur acquires US orthotics company Royce Medical

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 24, 2020 , ... ... of chronic inflammatory and fibrotic diseases, today announced that Dr. Stacie Canan has ... Discovery. , Dr. Canan previously served as Executive Director of Global Health at ...
(Date:8/26/2020)... HOUSTON (PRWEB) , ... August 25, 2020 , ... ... it made Inc. magazine’s 2020 annual Inc. 5000 list. The list is the most ... list in 2019 as well, and for this year’s list, reported three-year revenue growth ...
(Date:8/21/2020)... ... August 19, 2020 , ... “How can ... businesses dedicated to Salivary Bioscience for more than twenty years. Together with Douglas ... Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva Research and Applications ," and ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 12, 2020 , ... ... International), a global leader in FDA compliance consulting has been named on its ... companies. The list represents a unique look at the most successful companies within ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now ... With 50 million stem cells total, patients may choose which extremities they would like ... arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained ...
(Date:7/31/2020)... and SOMERSET, N.J (PRWEB) , ... July 29, ... ... genome editing company, and Catalent, the leading global provider of advanced delivery technologies, ... health products, today announced that they have entered into a strategic partnership whereby ...
(Date:7/22/2020)... , ... July 22, 2020 , ... Join experts from ... Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar on ... regulating body in China for drugs and medical devices. Specifically, for medical devices, the ...
Breaking Biology Technology:
Cached News: